We have used a panel of bladder cancer cell lines to compare the toxicities of Adriamycin and epirubicin, two drugs used intravesically to treat superficial transitional cell cancer (TCC) of the bladder, alone and in combination with lonidamine, an agent known to be active against anthracycline-resi
In vitropotentiation by lonidamine of the cytotoxic effect of adriamycin on primary and established breast cancer cell lines
โ Scribed by Saverio Savini; Wainer Zoli; Oriana Nanni; Annalisa Volpi; G. Luca Frassineti; Enrico Magni; Alberto Flamigni; Andrea Amadori; Dino Amadori
- Publisher
- Springer US
- Year
- 1992
- Tongue
- English
- Weight
- 652 KB
- Volume
- 24
- Category
- Article
- ISSN
- 0167-6806
No coin nor oath required. For personal study only.
๐ SIMILAR VOLUMES
An increase in the therapeutic effects of cancer chemotherapeutic agents and circumvention of drug resistance in cancer cells might result from an increase in the intracellular drug level. Alteration of the lipid domain of the cell membrane can result in a higher intracellular drug level. This alter
In this study the ability of the new pure anti-estrogen IcI 182,780 to modulate the cytotoxic action of adriamycin (ADR) on parental and ADR-resistant MCF-7 (MCF-7 ADRr) human breast-cancer cells was investigated and compared with that of tamoxifen (TAM). TAM enhanced ADR cytotoxicity in MCF-7 ADRr